BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CTMSS - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CTMSS
X-ORIGINAL-URL:https://clinicaltmssociety.org
X-WR-CALDESC:Events for CTMSS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201118
DTEND;VALUE=DATE:20201119
DTSTAMP:20260614T013453
CREATED:20201107T195259Z
LAST-MODIFIED:20241118T202658Z
UID:1500-1605657600-1605743999@clinicaltmssociety.org
SUMMARY:CTMSS Product Theater Webinar with MAGVENTURE
DESCRIPTION:CTMSS Product Theater Webinar - ON-DEMAND\n \nDate: Wednesday\, November 18\, 2020\nFormat: On-Demand \nThe Advantages of Robotic TMS in The Context of The COVID-19 Pandemic \nThe TMS-Cobot is the only FDA cleared robotic TMS solution for MagVenture TMS Therapy. MagVenture is proud to be partners with Axilum Robotics in offering a solution to significantly eliminate patient operator contact during routine TMS procedures. \nWhat are the general advantages of The TMS-Cobot? \n\nThe TMS-Cobot\, with its optical Tracking System\, controls the real-time position\, orientation and tilt of the TMS coil during the session. There is no need for the operator to adjust coil position during the session.\nAutomatically compensates for potential head motion during the TMS session and reduces the movement constraint of the patient.\nMaintains contact between the coil and head with its integrated contact sensor.\n\nLearning objectives \n\nIntroduction to Robotic TMS;\nTMS-Cobot implementation and how it works to reduce patient and operator interaction;\nDemonstration of the FDA cleared TMS-Cobot.\n\nFormat: LIVE \nFREE TO REGISTER! \n**Webinar log-in information will be sent out via email. \nDisclaimer: The content does not necessarily reflect the views and opinions of the Clinical TMS Society or its members and is solely determined by the sponsor. \n\nPresenters: \n\nMichel Berg\, MD\, CEO of Axilum Robotics \nDr. Berg is a medical doctor and a business school graduate\, he built his experience within the pharmaceutical and medical device industry before co-founding Axilum Robotics in 2011 with a team of experts in medical robotics. \n\nRustin Berlow\, MD \nDr. Berlow is a psychiatrist in a California private practice with years of TMS experience. He graduated from Columbia University College of Physicians and Surgeons medical school in 1990. After 23 years of psychopharmacology Dr. Berlow added procedural diagnosis & brain stimulation. Initial visit includes HRV\, GSR and EEG. Magnetic stim: rTMS\, TBS\, accelerated\, deep TMS. Electric stim: tDCS\, tACS\, Trigeminal and tVNS (Transcutaneous Vagus Nerve Stimulation). EEG-TMS - how to predict and personalize treatment). \n\n\n\nWhen\nNovember 18th\, 2020 from  5:00 PM to  6:00 PM
URL:https://clinicaltmssociety.org/event/ctmss-product-theater-webinar-with-magventure/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/MagVenture_Product_Theater_Event_Thumbnail.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200929
DTEND;VALUE=DATE:20241108
DTSTAMP:20260614T013453
CREATED:20241107T195053Z
LAST-MODIFIED:20241108T134600Z
UID:1498-1601337600-1731023999@clinicaltmssociety.org
SUMMARY:CTMSS Product Theater Webinar with NEUROSTAR
DESCRIPTION:CTMSS Product Theater Webinar\n \nDate: Tuesday\, September 29\, 2020\nTime: 5:00 pm PDT / 7:00 pm CDT / 8:00 pm EDT \nTreating Depression Episodes – New Research Data before Publication\nEfficacy of NeuroStar TMS in Bipolar and Unipolar Depression \nTreatment of Bipolar Depression: A Pilot Study presented by Scott Aaronson\, M.D. \nThe majority of time patients with bipolar disorder are ill\, they are depressed.  There are few FDA approved treatments for bipolar depression and all of them are second-generation antipsychotics which carry a high side effect burden.  Clinical experience has suggested that TMS might be effective for bipolar depression.  This presentation will review the existing literature on the efficacy of TMS for bipolar depression and present the findings from a two-center open-label prospective trial of TMS in bipolar depression including type I and type II patients. \nAt the end of the presentation\, attendees will gain an understanding of the existing literature on the efficacy of TMS for bipolar depression and learn additional insights from an examination of a two-center open-label trial. \nClinical Outcomes of NeuroStar TMS treatment: The Largest Patient Registry for Depression Treatment with Transcranial Magnetic Stimulation presented by Harold Sackeim\, Ph.D. \nNeuroStar® Advanced Therapy System Clinical Outcomes Registry has documented treatment parameters and clinical outcomes in over 9\,000 unique individuals treated at over 100 private practice sites in the US. This presentation reports new findings regarding the efficacy of TMS in adult patients treated for an episode of major depressive disorder in community settings.  Demographic and treatment parameter correlates of treatment outcomes will be examined.  New findings will also be presented regarding the relative efficacy of the Standard NeuroStar protocol (inter-train interval of 26 s; 38-minute session) and the Dash protocol (inter-train interval of 11 s; 19-minute session). \nAt the end of the presentation\, attendees will gain insights into the real-world treatment outcomes of MDD and the efficacy of TMS leveraging the largest clinical data set in MDD. \nFormat: LIVE \nFREE TO REGISTER! \nRegister online by Monday\, September 28\, 2020. \n**Webinar log-in information will be sent out via email the day prior on September 28\, 2020. \nDisclaimer: The content does not necessarily reflect the views and opinions of Clinical TMS Society or its members and is solely determined by the sponsor. \n\nPresenters: \n\nScott Aaronson\, M.D. \nDr. Scott Aaronson is director of clinical research programs\, director of transcranial magnetic stimulation services\, and chair of the medical executive committee at Sheppard Pratt Health System in Baltimore\, Maryland. He is an Adjunct Professor in the Department of Psychiatry at the University of Maryland School of Medicine. Dr. Aaronson specializes in treatment-resistant affective disorders. He is a thought leader in the areas of biological psychiatry\, diagnosis\, and the integration of somatic and psychological therapies\, and is the principal investigator for multiple studies on the development of novel therapies for mood and anxiety disorders. Dr. Aaronson is a valued speaker and educator and frequently lectures both regionally and nationally on mood disorders\, including the integration of biological and psychotherapies\, complex mood disorders\, psychoeducation\, and the development of new therapies. Much of his research work and publications center on the development of various neurostimulation paradigms including Transcranial Magnetic Stimulation\, Vagus Nerve Stimulation\, Direct Current Stimulation\, and synchronized TMS to treat severe mood disorders.  Recently\, he has begun research into the use of psychedelics in mood disorders including three studies looking at psilocybin in various presentations of depression.  He is a member of the board of directors of the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr Aaronson earned his MD with honors from Harvard Medical School. He completed a residency in psychiatry at McLean Hospital\, as well as a fellowship in sleep physiology at Harvard Medical School.  He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American College of Psychiatrists. \n\nHarold A. Sackeim\, Ph.D. \nDr. Harold A. Sackeim is Professor of Clinical Psychology in Psychiatry and Radiology\, College of Physicians and Surgeons\, Columbia University.  He served as Chief of the Department of Biological Psychiatry at the New York State Psychiatric Institute for 25 years. He is also the Founding Editor of the journal\, Brain Stimulation: Basic\, Translational\, and Clinical Research in Neuromodulation.  He received his first B.A. from Columbia College\, Columbia University (1972)\, another B.A. and an M.A. from Magdalen College\, Oxford University (1974) and his Ph.D. from the University of Pennsylvania (1977)\, where he also completed his clinical training in the Department of Psychiatry. He joined the faculty of Columbia University in 1977\, where he remains today. \n\n\n\nWhen\nSeptember 29th\, 2020 from  5:00 PM to  6:00 PM
URL:https://clinicaltmssociety.org/event/ctmss-product-theater-webinar-with-neurostar/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/NeuroStar_Product_Theater_Event_Thumbnail.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200902
DTEND;VALUE=DATE:20200903
DTSTAMP:20260614T013453
CREATED:20241107T194804Z
LAST-MODIFIED:20241108T134118Z
UID:1495-1599004800-1599091199@clinicaltmssociety.org
SUMMARY:CTMSS Product Theater Webinar
DESCRIPTION:CTMSS Product Theater Webinar\n \nDate: Tuesday\, September 22\, 2020\nTime: 5:00 pm PDT / 7:00 pm CDT / 8:00 pm EDT \nStimGuide\, An Innovative Solution to Optimize TMS Treatments\nAdoption of 3D Navigation with EMG in the Clinical Practice Setting \nThis session will provide an overview of the workflow for the StimGuide 3D Navigation System and how it can be used in the clinical setting to improve: \n\nPrecise and consistent coil placement\nQuality control and consistency for both novice and expert TMS technicians\nSimplifying MT determination utilizing EMG option\n\nSession Objectives: Upon completion of the presentation\, the participant should have a clear understanding about how 3D navigation and EMG can be used in the clinical setting to optimize TMS treatments\, and how it differs from other navigation systems that require an MRI.  Specifically\, the following aspects will be covered: \n\nRegistration of treatment target(s) and how these can be recalled for subsequent treatment sessions to ensure reliable coil positioning for both novice and expert technicians.\nPositioning the coil in the pre-determined treatment target by aligning the 4 parameters (xy location\, contact\, tilt\, & rotation) within the specified tolerances\nUtilizing EMG to facilitate rMT Determination\nTracking and monitoring coil position in real-time to maintain consistent positioning during a treatment\nHow StimGuide can be used as a quality management tool for clinical sites that have multiple technicians and treaters\n\nFormat: LIVE \nFREE TO REGISTER! \nRegister online by Monday\, September 21\, 2020. \n**Webinar log-in information will be sent out via email the day prior on September 21\, 2020. \nDisclaimer: The content does not necessarily reflect the views and opinions of Clinical TMS Society or its members and is solely determined by the sponsor. \n\nPresenters: \n\nFoster\, Lance C\, MD \nDr. Lance Foster is a Child and Family Psychiatrist at Northwest Arkansas Psychiatry. He is Board Certified in General Psychiatry and also in Child and Adolescent Psychiatry by the American Board of Psychiatry and Neurology. He serves as an adjunct Associate Professor of Psychiatry at the University of Arkansas for Medical Sciences. Dr. Foster is a member of the Clinical TMS Society and provides TMS therapy for patients suffering from depression. Dr. Foster was the Chief Medical Officer and a staff psychiatrist at Ozark Guidance Center for 15 years. As a staff psychiatrist\, he provided psychiatric care for preschool through adult\, Therapeutic Day Treatment programs\, and the Child and Adolescent residential program. Dr. Foster is professionally affiliated with the American Psychiatric Association\, Arkansas Psychiatric Society\, American Academy of Child and Adolescent Psychiatry\, and the American College of Physician Executives. \n\nStaley\, Randall\, MD \nDr. Randall Staley joined Northwest Arkansas Psychiatry in 2018. Dr. Staley is board certified in Child and Adolescent Psychiatry and Adult Psychiatry by the American Board of Psychiatry and Neurology. He has practiced primarily with children and adolescents for more than 10 years\, working with ADHD and other issues in Northwest Arkansas. Dr. Staley is a member of the Clinical TMS Society and provides TMS therapy for patients suffering from depression. \n\n\n\nWhen\nSeptember 22nd\, 2020 from  5:00 PM to  6:00 PM
URL:https://clinicaltmssociety.org/event/1495/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Magstim_Product_Theater_Event_Thumbnail_V2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200803
DTEND;VALUE=DATE:20241108
DTSTAMP:20260614T013453
CREATED:20241107T194636Z
LAST-MODIFIED:20241108T134638Z
UID:1493-1596412800-1731023999@clinicaltmssociety.org
SUMMARY:TOP 6 Flash Poster Presentations Webinar
DESCRIPTION:TOP 6 Flash Poster Presentations Webinar \nTuesday\, August 4\, 2020\n8 pm EDT\, 7 pm CDT and 5 pm PDT\nSince 2018\, CTMSS has provided a speaking platform for the Top 4 Poster Abstracts at the Annual Meeting. We are thrilled to be able to continue to share our top research and findings. \nThe Abstract Review Committee decided to include an additional two abstracts this year to be presented since the 2020 Annual Meeting in Chicago was regrettably canceled. These abstracts were originally scheduled as general presentations for the conference and as such\, were not eligible for being selected to present during this session. Thus\, this year there will be a total of 6 top abstracts presented. \nThe following Top 6 Poster Presentations Webinar is scheduled for Tuesday\, August 4\, 2020\, and will be moderated by our Abstract Review Committee\, F. Andrew Kozel\, M.D.\, M.S.C.R. \n\nAbstract #6: Anhedonia in Major Depressive Disorder: Can it be the Chicken and the Egg for Transcranial Magnetic Stimulation?\nAbstract #17: Does it Matter if Depressed Patients get TMS Sessions Less Often than 5 Times per Week? A Treatment Schedule Density Analysis\nAbstract #25: Systematic Review and Meta-Analysis Comparing iTBS vs. TMS vs. Sham in Randomized Controlled Trials\nAbstract #41: Evaluation of Cognitive Performance in Clinically Depressed Patients Using THINC-it® After rTMS Treatment\nAbstract #45: A Multicenter\, Randomized\, Sham-Controlled Trial of Left Prefrontal\, 10 Hz\, Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression\nAbstract #64: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT-TRD) Induces Rapid remission from Treatment-Resistant Depression in a Double-Blinded\, Randomized\, and Controlled Trial\n\nCME will not be provided for this webinar. \nFREE TO REGISTER! \nFormat: Webinar using Zoom Video Communications \n*The Webinar log-in information will be sent out via email the day prior and the morning of the webinar. \nOnline registration ENDS Monday\, August 3\, 2020\, at 3 pm PDT
URL:https://clinicaltmssociety.org/event/top-6-flash-poster-presentations-webinar/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Top_6_Abstract_Webinar_Recordings.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200506
DTEND;VALUE=DATE:20200507
DTSTAMP:20260614T013453
CREATED:20241107T194539Z
LAST-MODIFIED:20241108T134210Z
UID:1491-1588723200-1588809599@clinicaltmssociety.org
SUMMARY:2020 Annual Member Meeting Webinar
DESCRIPTION:Please join the Society President\, Todd Hutton\, MD and Executive Director\, Ashleigh Servadio\, MSC\, for the Society’s Annual Member Meeting webinar on Wednesday\, May 6\, 2020 at 4:00 PM (PDT) / 7:00 PM (EDT). \nPresident\, Todd Hutton\, MD will provide a recap of the 2019-2020 year and we will also introduce the newly elected 2020-2021 Board of Directors. \nThis meeting is only for current CTMSS members.
URL:https://clinicaltmssociety.org/event/2020-annual-member-meeting-webinar/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Annual_Member_Meeting_event_thumbnail.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191107
DTEND;VALUE=DATE:20191108
DTSTAMP:20260614T013453
CREATED:20241107T194414Z
LAST-MODIFIED:20241108T134715Z
UID:1487-1573084800-1573171199@clinicaltmssociety.org
SUMMARY:2019 Annual Member Meeting Webinar
DESCRIPTION:Please join the Society President\, Todd Hutton\, MD\, Immediate Past President\, Paul Croarkin\, DO and Executive Director\, Ashleigh Servadio\, MSC for the society’s annual members meeting webinar on Wednesday\, July 31\, 2019 at 5:30 PM (PDT). \nListen to updates on the society and learn more about the 2019-2020 Board of Directors. \nThis meeting is only for current CTMSS members. \nNo longer available
URL:https://clinicaltmssociety.org/event/2019-annual-member-meeting-webinar/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Annual_Member_Meeting_event_thumbnail.jpg
END:VEVENT
END:VCALENDAR